Valuation: Intellia Therapeutics, Inc.

Market Cap 1.8B 1.54B 1.44B 1.32B 2.48B 172B 2.51B 17.04B 6.64B 86.48B 6.76B 6.61B 286B P/E 2026 *
-4.02x
P/E 2027 * -4.86x
Enterprise Value 1.46B 1.25B 1.17B 1.07B 2.01B 140B 2.04B 13.84B 5.4B 70.23B 5.49B 5.37B 232B EV / Sales 2026 *
28.2x
EV / Sales 2027 * 11.3x
Free-Float
96.14%
Yield 2026 *
-
Yield 2027 * -
1 day+3.22%
1 week+7.81%
Current month+20.22%
1 month+15.68%
3 months+1.90%
6 months-2.43%
Current year+42.83%
1 week 11.44
Extreme 11.44
13.35
1 month 10.15
Extreme 10.15
13.35
Current year 9.05
Extreme 9.05
18.48
1 year 7.95
Extreme 7.95
28.25
3 years 5.9
Extreme 5.9
38.79
5 years 5.9
Extreme 5.9
180.59
10 years 5.9
Extreme 5.9
202.73
Manager TitleAgeSince
Chief Executive Officer 68 2017-12-31
Director of Finance/CFO 51 2024-07-21
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 2014-06-30
Chairman 63 2020-01-31
Director/Board Member 74 2018-10-30
Date Insider Type Main position Quantity % Market Cap.
7/22/26 Sell

Chief Financial Officer

-8,111 0.0058%
7/2/26 Sell

Chief Financial Officer

-4,677 0.0033%
7/1/26 Sell

Controller/Auditor

-2,641 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
+3.22%+7.81%+22.05%-66.52% 1.8B
+1.09%+5.26%+4.52%+23.38% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+29.84% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.73%+4.77%+76.32%+101.42% 27.83B
Weighted average by Cap. +0.50%+4.74%+99.04%+139.95%

Financials

2026 *2027 *
Net sales 51.88M 44.44M 41.58M 38.06M 71.43M 4.96B 72.38M 491M 192M 2.49B 195M 191M 8.25B 125M 107M 101M 92.06M 173M 12.01B 175M 1.19B 463M 6.03B 471M 461M 19.95B
Net income -420M -360M -337M -308M -578M -40.19B -586M -3.98B -1.55B -20.19B -1.58B -1.54B -66.77B -374M -321M -300M -275M -516M -35.82B -522M -3.55B -1.38B -18B -1.41B -1.38B -59.52B
Net Debt -338M -290M -271M -248M -466M -32.35B -472M -3.2B -1.25B -16.25B -1.27B -1.24B -53.76B -376M -322M -302M -276M -518M -36.01B -525M -3.56B -1.39B -18.09B -1.41B -1.38B -59.82B
Logo Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Employees
377
Date Price Change Volume
26-08-21 US$12.84 +3.22% 3,347,693
26-08-20 US$12.44 -6.33% 4,703,599
26-08-19 US$13.28 +14.48% 6,114,892
26-08-18 US$11.60 -4.05% 3,178,625
26-08-17 US$12.09 +1.51% 1,818,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
12.84USD
Average target price
23.94USD
Spread / Average Target
+86.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTLA Stock